Valuation: Galapagos NV

Market Cap 1.67B 1.88B 1.88B 1.56B 1.42B 2.68B 180B 2.7B 18.83B 7.3B 92.23B 7.05B 6.89B 296B P/E 2026 *
-13.6x
P/E 2027 * -5.51x
Enterprise Value -763M -859M -859M -712M -649M -1.22B -82.56B -1.24B -8.62B -3.34B -42.21B -3.22B -3.15B -135B EV / Sales 2026 *
-6.51x
EV / Sales 2027 * 3.7x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.23%-0.59%+52.63%+128.54% 43.39B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2026 *2027 *
Net sales 117M 132M 132M 109M 99.72M 188M 12.68B 190M 1.32B 513M 6.48B 495M 485M 20.81B 41.9M 47.16M 47.16M 39.1M 35.64M 67.22M 4.53B 67.85M 473M 183M 2.32B 177M 173M 7.44B
Net income -40.7M -45.8M -45.8M -37.98M -34.62M -65.29M -4.4B -65.9M -460M -178M -2.25B -172M -168M -7.22B -213M -239M -239M -199M -181M -341M -23.01B -344M -2.4B -931M -11.76B -899M -879M -37.76B
Net Debt -2.43B -2.74B -2.74B -2.27B -2.07B -3.9B -263B -3.94B -27.45B -10.64B -134B -10.27B -10.05B -431B -1.51B -1.7B -1.7B -1.41B -1.29B -2.43B -164B -2.45B -17.08B -6.62B -83.65B -6.39B -6.25B -268B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B